Dexfenfluramine in obese Chinese NIDDM patients: A placebo-controlled investigation of the effects on body weight, glycemic control, and cardiovascular risk factors

Diabetes Care

Volumn 20, Issue 7, 1997, Pages 1122-1127

  Chow, Chun Chung ^a,b   Ko, Gary T C ^a   Tsang, Lynn W W ^a   Yeung, Vincent T F ^a   Chan, Juliana C N ^a   Cockram, Clive S ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

DEXFENFLURAMINE; HEMOGLOBIN A1C;

ADULT; ARTICLE; CALORIC RESTRICTION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; GLUCOSE TOLERANCE; HUMAN; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL DRUG ADMINISTRATION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; WEIGHT REDUCTION; WELLBEING;

EID: 0030943494     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.20.7.1122     Document Type: Article

References (33)

1. Cockram CS, Woo J, Lau E, Chan JCN, Chan AYW, Lau J, Swaminathan R, Donnan SPB: The prevalence of diabetes mellitus and impaired glucose tolerance among Hong Kong Chinese adults of working age. Diabetes Res Clin Pract 21:67-73, 1993
2. Chou P, Chen HH, Hsiao KJ: Community-based epidemiological study on diabetes in Pu-Lt, Taiwan. Diabetes Care 15:81-89, 1992
3. Thai AC, Yeo PPB, Lun KC, Hughes K, Wang KW, Sothy SP, Lui KF, Ng WY, Cheah JS, Phoon WO, Lim P: Changing prevalence of diabetes mellitus in Singapore over a ten year period. J Med Assoc Thai 70 (Suppl. 2):63-67, 1987
4. Dowse GK, Zimmet PZ, Gareeboo H, Alberti GKMM, Tuomilehto J, Finch CF, Chitson P, Tulsidas H: Abdominal obesity and physical inactivity as risk factors for NIDDM and impaired glucose tolerance in Indian, Creole, and Chinese Mauritians. Diabetes Care 14:271-282, 1991
5. Chan JCN, Cheung CK, Swaminathan R, Nicholls MG, Cockram CS: Obesity, albuminuria and hypertension among Hong Kong Chinese with non-insulin-dependent diabetes mellitus (NIDDM). Postgrad Med J 69:204-210, 1993
6. Zimmet P, Dowse GK, Finch C: The epidemiology of NIDDM. Int Diabetes Fed Bull 35:3-8, 1990
7. Olefsky J, Reaven GM, Farquar JW: Effects of weight reduction on obesity studies of lipid and carbohydrate metabolism in normal and hyperlipoproteinaemic subjects. J Clin Invest 53:64-76, 1974
8. Wing RR, Koeske R, Epstein HH, Nowalk MP, Gooding W, Becker D: Long term effects of modest weight loss in type II diabetic patients. Arch Intern Med 147:1749-1753, 1987
9. Kelley DE, Wing R, Buonocore C, Stuns J, Polonsky K, Fitzsimmons M: Relative effects of caloric restriction and weight loss in non-insulin-dependent diabetes mellitus. J Clin Endocrinol Metab 77:1287-1293, 1993
10. Watts NB, Spanheimer RG, DiGirolamo M, Gebhart SSP, Musey VC, Siddiq YK, Phillips LS: Prediction of glucose response to weight loss in patients with non-insulin-dependent diabetes mellitus. Arch Intern Med 150:803-806, 1990
11. Lean MEJ, Pownie JK, Anderson AS, Garth-waite PH: Obesity, weight loss and prognosis in type 2 diabetes. Diabet Med 7:228-223, 1990
12. Weintraub M: Long-term weight control study: conclusions. Clin Pharmacol Ther 51:642-646, 1992
13. Guy-Grand B, Crepaldi G, Lefebvre P, Apfelbaum M, Gries A, Turner P: International trial of long-term dexfenfluramine in obesity Lancet ii:1142-1145, 1989
14. Noble RE: A six-month study of the effects of dexfenfluramine on partially successful dieters. Curr Ther Res 47:612-619, 1990
15. Finer N, Craddock D, Lavielle R, Keen H: Effect of 6 months therapy with dexfenfluramine in obese patients: studies in the United Kingdom. Clin Neuropharmacoi 11 (Suppl.):179-186, 1988
16. Enzi G, the DIMOS Group: Dexfenfluramine Italian Multicentre Open Study (DIMOS)-efficacy and safety of dexflenfluramine in the treatment of patients with simple or complicated obesity Clin Drug Invest 10:249-256, 1995
17. Willey KA, Molyneaux LM, Overland JE, Yue DK: The effects of dexfenfluramine on blood glucose control in patients with type 2 diabetes. Diabet Med 9:341-343, 1992
18. Stewart GO, Stein GR, Davis TME, Find-later P: Dexfenfluramine in type II diabetes: effect on weight and diabetes control. Med J Aust 158:167-169, 1993
19. Manning RM, Jung RT, Leese GP, Newton RW: The comparison of four weight reduction strategies aimed at overweight diabetic patients. Diabet Med 12:409-415, 1995
20. Scheen AJ, Paolisso G, Salvatore T, Lefebvre PJ: Improvement of insulin-induced glucose disposal in obese patients with NIDDM after 1-week treatment with d-fenfluramine. Diabetes Care 14:325-332, 1991
21. Marks SJ, Moore NR, Clark ML, Strauss BJG, Hockaday TDR: Reduction of visceral adipose tissue and improvement of metabolic indices: effect of dexfenfluramine in NIDDM. Obes Res 4:1-7, 1996
22. Andersen PH, Richelsen B, Bak J, Schmitz O, Sorensen NS, Lavielle R, Pedersen O: Influence of short-term dexfenfluramine therapy on glucose and lipid metabolism in obese non-diabetic patients. Acta Endocinol 128:251-258, 1993
23. Bremer JM, Scott RS, Lintott CJ: Dexfenfluramine reduces cardiovascular risk factors. Int J Obes 18:199-205, 1994
24. Holdaway IM, Wallace E, Westbrooke L, Gamble G: Effect of dexfenfluramine on body weight, blood pressure, insulin resistance and serum cholesterol in obese individuals. Int J Obes 19:749-751, 1995
25. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DE, Turner RC: Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diobetologia 28:412-419, 1985
26. Pi-Sunyer FX: Medical hazards of obesity Ann Intern Med 119:655-660, 1993
27. Manson JE, Willett WC, Stampfer MJ, Colditz GA, Hunter DJ, Hankinson SE, Hennekens CH, Speizer FE: Body weight and mortality in women. N Engl J Med 333:677-685, 1995
28. Seidell JC, Deerenberg I: Obesity in Europe: prevalence and consequences for use of medical care. Pharmacoeconomics 5:38-44, 1994
29. Wolf AM, Colditz GA: The cost of obesity: the US perspective. Pharmacoeconomics 5: 34-37, 1994
30. Drouin P, Hanotin C, Thomas F, Leutenegger E: Efficacy and tolerability of sibutramine versus dexfenfluramine in obese patients. Int J Obes 19 (Suppl. 2):394, 1995
31. O'Connor HT, Richman RM, Steinbeck SK, Caterson ID: Dexfenfluramine treatment of obesity: a double blind trial with post trial follow up. Int J Obes 19:181-189, 1995
32. Abenhaim L, Moride Y, Brenot F, Rich S, Benichou J, Kurz X, Higenbottam T, Oakley C, Wouters E, Aubier M, Simonneau G, Begaud B: Appetite-suppressant drugs and the risk of primary pulmonary hypertension. N Engl J Med 335:609-616, 1996
33. Manson JE, Faich GA: Pharmacotherapy for obesity: do the benefits outweight the risks? N Engl J Med 335:659-660, 1996